 Anosheh Afghahi
Concepts (143)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 13 | 2023 | 2059 | 1.750 |
Why?
| | Triple Negative Breast Neoplasms | 4 | 2018 | 167 | 1.480 |
Why?
| | BRCA2 Protein | 3 | 2022 | 44 | 0.770 |
Why?
| | BRCA1 Protein | 3 | 2022 | 58 | 0.770 |
Why?
| | Dyspareunia | 1 | 2020 | 9 | 0.730 |
Why?
| | Cancer Survivors | 2 | 2022 | 234 | 0.680 |
Why?
| | Sexual Health | 1 | 2020 | 54 | 0.660 |
Why?
| | Lymphocyte Count | 1 | 2018 | 140 | 0.600 |
Why?
| | Genetic Testing | 2 | 2017 | 401 | 0.590 |
Why?
| | Biomarkers, Tumor | 3 | 2018 | 1080 | 0.540 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 2015 | 58 | 0.490 |
Why?
| | Chromosome Aberrations | 1 | 2015 | 144 | 0.490 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2018 | 912 | 0.490 |
Why?
| | DNA Copy Number Variations | 1 | 2015 | 169 | 0.470 |
Why?
| | Genomics | 2 | 2016 | 726 | 0.450 |
Why?
| | Germ-Line Mutation | 3 | 2019 | 137 | 0.420 |
Why?
| | Molecular Targeted Therapy | 1 | 2015 | 361 | 0.410 |
Why?
| | Genetic Predisposition to Disease | 2 | 2017 | 2382 | 0.370 |
Why?
| | Gene Expression Profiling | 1 | 2016 | 1642 | 0.330 |
Why?
| | Antineoplastic Agents | 2 | 2016 | 2009 | 0.300 |
Why?
| | Genes, BRCA1 | 2 | 2017 | 34 | 0.280 |
Why?
| | SEER Program | 2 | 2018 | 206 | 0.270 |
Why?
| | Neoplasm Staging | 2 | 2018 | 1251 | 0.220 |
Why?
| | Amyloidosis | 2 | 2013 | 42 | 0.210 |
Why?
| | Circulating Tumor DNA | 1 | 2022 | 23 | 0.210 |
Why?
| | Prophylactic Mastectomy | 1 | 2021 | 6 | 0.190 |
Why?
| | Female | 16 | 2023 | 64889 | 0.190 |
Why?
| | Middle Aged | 10 | 2022 | 29112 | 0.190 |
Why?
| | Neoplasms | 1 | 2015 | 2340 | 0.190 |
Why?
| | Receptor, ErbB-2 | 3 | 2023 | 327 | 0.190 |
Why?
| | Chemoprevention | 1 | 2021 | 99 | 0.180 |
Why?
| | Resistance Training | 1 | 2022 | 137 | 0.180 |
Why?
| | Humans | 19 | 2023 | 125131 | 0.170 |
Why?
| | Neoadjuvant Therapy | 2 | 2023 | 338 | 0.170 |
Why?
| | Aged | 6 | 2018 | 20859 | 0.170 |
Why?
| | Mutation | 3 | 2022 | 3520 | 0.160 |
Why?
| | Cyclin-Dependent Kinase 4 | 1 | 2018 | 33 | 0.160 |
Why?
| | Cyclin-Dependent Kinase 6 | 1 | 2018 | 37 | 0.160 |
Why?
| | Carcinoma, Lobular | 1 | 2018 | 56 | 0.150 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2018 | 63 | 0.150 |
Why?
| | Hereditary Breast and Ovarian Cancer Syndrome | 1 | 2017 | 3 | 0.150 |
Why?
| | Genes, BRCA2 | 1 | 2017 | 26 | 0.140 |
Why?
| | Penetrance | 1 | 2017 | 28 | 0.140 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 116 | 0.140 |
Why?
| | Platinum | 1 | 2017 | 40 | 0.140 |
Why?
| | California | 1 | 2018 | 385 | 0.140 |
Why?
| | Carboplatin | 1 | 2017 | 144 | 0.140 |
Why?
| | Colonic Neoplasms | 1 | 2018 | 230 | 0.130 |
Why?
| | Adult | 7 | 2022 | 33167 | 0.130 |
Why?
| | Mortality | 1 | 2018 | 327 | 0.130 |
Why?
| | Imatinib Mesylate | 1 | 2015 | 63 | 0.130 |
Why?
| | Trastuzumab | 1 | 2015 | 94 | 0.120 |
Why?
| | Physicians | 1 | 2023 | 836 | 0.120 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2023 | 1442 | 0.120 |
Why?
| | Proportional Hazards Models | 1 | 2018 | 1191 | 0.120 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2015 | 93 | 0.120 |
Why?
| | Neoplasm Grading | 1 | 2015 | 263 | 0.120 |
Why?
| | Clinical Decision-Making | 1 | 2017 | 292 | 0.120 |
Why?
| | Prognosis | 2 | 2023 | 3616 | 0.120 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2015 | 325 | 0.120 |
Why?
| | Neoplasm Invasiveness | 1 | 2015 | 472 | 0.110 |
Why?
| | Melphalan | 1 | 2013 | 30 | 0.110 |
Why?
| | Immunoglobulin Light Chains | 1 | 2013 | 35 | 0.110 |
Why?
| | Thalidomide | 1 | 2013 | 29 | 0.110 |
Why?
| | Quality of Life | 2 | 2022 | 2580 | 0.110 |
Why?
| | Disease Management | 1 | 2017 | 599 | 0.110 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2017 | 677 | 0.100 |
Why?
| | Laryngeal Diseases | 1 | 2012 | 23 | 0.100 |
Why?
| | Ultraviolet Rays | 1 | 2015 | 417 | 0.100 |
Why?
| | Immunotherapy | 1 | 2015 | 499 | 0.090 |
Why?
| | Macrophages | 1 | 2018 | 1333 | 0.090 |
Why?
| | Dexamethasone | 1 | 2013 | 329 | 0.090 |
Why?
| | Prevalence | 1 | 2017 | 2488 | 0.090 |
Why?
| | Registries | 1 | 2018 | 2050 | 0.080 |
Why?
| | Heart Diseases | 1 | 2013 | 364 | 0.080 |
Why?
| | Electronic Health Records | 1 | 2016 | 875 | 0.080 |
Why?
| | Delivery of Health Care | 1 | 2016 | 925 | 0.080 |
Why?
| | Melanoma | 1 | 2015 | 714 | 0.080 |
Why?
| | Risk Assessment | 1 | 2017 | 3274 | 0.070 |
Why?
| | Biomarkers | 1 | 2018 | 3736 | 0.070 |
Why?
| | Smoking | 1 | 2015 | 1635 | 0.070 |
Why?
| | Skin Neoplasms | 1 | 2015 | 852 | 0.070 |
Why?
| | Aged, 80 and over | 2 | 2015 | 6936 | 0.070 |
Why?
| | Risk Factors | 1 | 2017 | 9549 | 0.050 |
Why?
| | Information Seeking Behavior | 1 | 2023 | 39 | 0.050 |
Why?
| | Peptide YY | 1 | 2022 | 13 | 0.050 |
Why?
| | Ghrelin | 1 | 2022 | 33 | 0.050 |
Why?
| | Sensation | 1 | 2022 | 48 | 0.050 |
Why?
| | Homologous Recombination | 1 | 2022 | 22 | 0.050 |
Why?
| | Lung Neoplasms | 1 | 2015 | 2244 | 0.050 |
Why?
| | Breast | 1 | 2023 | 153 | 0.050 |
Why?
| | Appetite | 1 | 2022 | 63 | 0.050 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2023 | 369 | 0.050 |
Why?
| | Body Image | 1 | 2022 | 76 | 0.050 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2022 | 76 | 0.050 |
Why?
| | Cross-Over Studies | 1 | 2022 | 485 | 0.050 |
Why?
| | Surveys and Questionnaires | 2 | 2023 | 5061 | 0.050 |
Why?
| | Mammography | 1 | 2021 | 130 | 0.040 |
Why?
| | Energy Intake | 1 | 2022 | 463 | 0.040 |
Why?
| | Young Adult | 1 | 2015 | 11384 | 0.040 |
Why?
| | Haploinsufficiency | 1 | 2019 | 49 | 0.040 |
Why?
| | Health Education | 1 | 2022 | 337 | 0.040 |
Why?
| | Aromatase Inhibitors | 1 | 2018 | 52 | 0.040 |
Why?
| | Retrospective Studies | 3 | 2021 | 13708 | 0.040 |
Why?
| | Receptors, CCR5 | 1 | 2018 | 54 | 0.040 |
Why?
| | Aminopyridines | 1 | 2018 | 86 | 0.040 |
Why?
| | Sexual Behavior | 1 | 2022 | 506 | 0.040 |
Why?
| | Mastectomy | 1 | 2018 | 130 | 0.040 |
Why?
| | Benzimidazoles | 1 | 2018 | 142 | 0.040 |
Why?
| | Purines | 1 | 2018 | 172 | 0.040 |
Why?
| | Receptors, Progesterone | 1 | 2018 | 327 | 0.030 |
Why?
| | Mice, Nude | 1 | 2018 | 673 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2018 | 573 | 0.030 |
Why?
| | Piperazines | 1 | 2018 | 331 | 0.030 |
Why?
| | Survival Analysis | 1 | 2019 | 1341 | 0.030 |
Why?
| | Receptors, Estrogen | 1 | 2018 | 392 | 0.030 |
Why?
| | Mice, Inbred BALB C | 1 | 2018 | 1233 | 0.030 |
Why?
| | Pyridines | 1 | 2018 | 445 | 0.030 |
Why?
| | Cell Movement | 1 | 2018 | 913 | 0.030 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2018 | 717 | 0.030 |
Why?
| | Protein Kinase Inhibitors | 1 | 2018 | 832 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2019 | 3326 | 0.020 |
Why?
| | Laryngoscopy | 1 | 2012 | 99 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2018 | 2913 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2013 | 1006 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2021 | 3309 | 0.020 |
Why?
| | Metastrongyloidea | 1 | 1969 | 1 | 0.020 |
Why?
| | Mollusca | 1 | 1969 | 6 | 0.020 |
Why?
| | Survival Rate | 1 | 2013 | 1799 | 0.020 |
Why?
| | Biopsy | 1 | 2012 | 1093 | 0.020 |
Why?
| | Pilot Projects | 1 | 2013 | 1530 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2012 | 1431 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2019 | 9790 | 0.020 |
Why?
| | Cohort Studies | 1 | 2013 | 5348 | 0.010 |
Why?
| | Mice | 1 | 2018 | 15984 | 0.010 |
Why?
| | Animals | 2 | 2018 | 34345 | 0.010 |
Why?
| | Male | 2 | 2013 | 60792 | 0.010 |
Why?
| | Parasitic Diseases, Animal | 1 | 1969 | 6 | 0.010 |
Why?
| | Snails | 1 | 1969 | 32 | 0.000 |
Why?
| | Dog Diseases | 1 | 1969 | 46 | 0.000 |
Why?
| | Ecology | 1 | 1969 | 108 | 0.000 |
Why?
| | Dogs | 1 | 1969 | 394 | 0.000 |
Why?
| | Aging | 1 | 1969 | 1706 | 0.000 |
Why?
|
|
Afghahi's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|